Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  PPD, Inc.    PPD

PPD, INC.

(PPD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

PPD : Named Clinical Research Company of the Year

11/02/2020 | 10:16am EST

PPD, Inc. (Nasdaq:PPD), was named the Clinical Research Company of the Year for winning multiple awards at the PharmaTimes Clinical Researcher of the Year competitions.

In addition to PPD winning the highest honor at the PharmaTimes International Clinical Researcher of the Year 2020 virtual awards ceremony, individual PPD clinical researchers won gold and bronze in both the Clinical Research Associate (CRA) and the Aspiring CRA awards, as well as gold and silver awards in the In-House CRA category and silver awards in the Team Leader and Start Up of the Year-Singles categories.

At the PharmaTimes Clinical Researcher of the Year 2020-The Americas online awards program, PPD won gold in the Experienced CRA and the New CRA categories, along with a silver for Strategic Partnership Team of the Year.

“Our clinical researchers displayed the utmost professionalism and competence in achieving this outstanding recognition from industry peers,” said Amber Lee, senior vice president of clinical operations for PPD. “We congratulate them on their accomplishments and recognize the talent, drive and dedication our clinical researchers bring to our clients and their research programs, which played a significant role in PPD being named the international clinical research company of the year.”

The industry recognition demonstrates the high caliber of PPD’s clinical research professionals and the importance of PPD’s award-winning training and development programs, such as the company’s Clinical Foundations Program and its CRA Academy. These programs help to prepare and equip research professionals to deliver high-caliber performance, quality and value to PPD customers.

The awards are the culmination of a rigorous series of assessments, including a three-stage competition concluding in presentations before a panel of experienced industry judges. The event was created to provide clinical research professionals an opportunity to benchmark their professional skills against their peers in a program of competency-based exercises developed through cross-industry collaboration.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 25,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.

This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the Securities and Exchange Commission (SEC), including our latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which is available on our website at https://investors.ppd.com or the SEC’s website at www.sec.gov. We assume no obligation and disclaim any duty to revise or update any forward-looking statements, or make any new forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.


© Business Wire 2020
All news about PPD, INC.
01/14PPD, INC. : Entry into a Material Definitive Agreement, Termination of a Materia..
AQ
01/11PPD, INC. : Regulation FD Disclosure (form 8-K)
AQ
01/11EQS-NEWS : Relief, NeuroRx and Quantum Leap announce the inclusion of ZYESAMI(TM..
DJ
01/06DAI ICHI KARKARIA : Gets Closure Order for Unit from Gujarat Pollution Control B..
MT
01/04PPD : to Present at the 39th Annual J.P. Morgan Healthcare Conference
BU
2020MODERNA : Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
AQ
2020PPD, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020PPD : Recognized as a Best Place to Work in Greater China
BU
2020EQS-NEWS : Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in..
DJ
2020MARKET CHATTER : US Clears New Drug Application for LG Chem’s Liver Diseas..
MT
More news
Financials (USD)
Sales 2020 4 586 M - -
Net income 2020 140 M - -
Net Debt 2020 3 428 M - -
P/E ratio 2020 90,9x
Yield 2020 -
Capitalization 12 762 M 12 762 M -
EV / Sales 2020 3,53x
EV / Sales 2021 3,10x
Nbr of Employees 23 000
Free-Float 61,2%
Chart PPD, INC.
Duration : Period :
PPD, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PPD, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 39,50 $
Last Close Price 36,50 $
Spread / Highest target 17,8%
Spread / Average Target 8,22%
Spread / Lowest Target -13,7%
EPS Revisions
Managers and Directors
NameTitle
David S. Simmons Chairman & Chief Executive Officer
William Jacob Sharbaugh Chief Operating Officer
Christopher G. Scully CFO, Treasurer, Executive VP & Assistant Secretary
David Johnston Executive VP-Global Clinical Development
Karen Kaucic Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PPD, INC.6.66%12 762
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601